Extrait

Background and study aims Head and neck cancer is a relatively uncommon type of cancer. Postoperative radiotherapy involves using doses of radiation to kill any cancer cells remaining after surgery to prevent the cancer from returning. If the radiation dose is inadequate or delivered to an inadequate area, this can lead to the tumour coming back (recurrence or relapse). The aim of this study is to look at the patterns of recurrence in head and neck cancer patients. Who can participate? Head and neck cancer patients with relapse who have previously undergone radiotherapy What does the study involve? Patient data is analysed to find out whether the relapse is related to the treatment they received. Radiotherapy data is analysed to look at the dose given in the primary tumour and relapse area in order to determine whether the relapse was the result of under-dosing of the primary tumour, and to find out whether treatment needs to be changed in order to avoid relapse in the future. There is no further treatment or follow up of the patients. What are the possible benefits and risks of participating? Future head and neck patients may benefit if the reason for relapse is found and treatment is changed in order to avoid it. No risks are involved. Where is the study run from? Oslo University Hospital (Norway) When is the study starting and how long is it expected to run for? January 2015 to October 2016 Who is funding the study? Oslo University Hospital (Norway) Who is the main contact? Dr Safora Johansen

Critère d'inclusion

• head and neck cancer

Liens

• isrctn